此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

EMPOWER™ 模块化起搏系统和 EMBLEM™ 皮下 ICD 通信抗心动过速起搏的有效性 (MODULAR ATP)

2026年11月9日 更新者:Boston Scientific Corporation

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

研究概览

地位

主动,不招人

详细说明

The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.

研究类型

介入性

注册 (实际的)

297

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Québec、加拿大
        • Institut Universitaire de Cardilogie et Pnuemologie de Quebec (IUCPQ)
    • Quebec
      • Montreal、Quebec、加拿大、H1T 1C8
        • Institut de Cardiologie de Quebec (Montreal Heart)
      • Linz、奥地利
        • Kepler Universitaetsklinikum
      • Brescia、意大利
        • Spedali Civil di Brescia
      • Cotignola、意大利
        • Maria Cecilia Hospital SPA
      • Naples、意大利、80131
        • AZ Osp Monaldi
      • Pisa、意大利、56126
        • Azienda Ospedaliero Universitaria Pisana
      • Prague、捷克语
        • Na Homolce Hospital
      • Grenoble、法国
        • CHU Grenoble - Hospital Michallon
      • Lille、法国、59000
        • CHRU de Lille
      • Nantes、法国
        • CHU de Nantes-Hopital Laennec
      • Paris、法国
        • Hospital European Georges-Pompidou
    • Arizona
      • Phoenix、Arizona、美国、85006
        • Banner University Medical Center Phoenix
      • Scottsdale、Arizona、美国、84258
        • Scottsdale Healthcare - Shea
    • Arkansas
      • Jonesboro、Arkansas、美国、72401
        • Arrhythmia Research Group
    • Florida
      • Orlando、Florida、美国、32803
        • AdventHealth Orlando
    • Georgia
      • Atlanta、Georgia、美国、30308
        • Emory University Hospital
    • Kentucky
      • Lexington、Kentucky、美国、40503
        • Baptist Health Lexington
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • New Jersey
      • Camden、New Jersey、美国、08103
        • Cooper Hospital - University Medical Center
    • New York
      • Manhasset、New York、美国、11030
        • Northwell University Hospital
      • New York、New York、美国、10029
        • Mount Sinai Medical Center
    • Ohio
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic
      • Columbus、Ohio、美国、43210
        • Ohio State University Medical Center
      • Columbus、Ohio、美国、43214
        • Ohio Health Research Institute
    • Pennsylvania
      • Hershey、Pennsylvania、美国、17033
        • Penn State Health Milton S. Hershey Medical Center
      • Philadelphia、Pennsylvania、美国、19104
        • Hospital of the University of Pennsylvania
    • Tennessee
      • Chattanooga、Tennessee、美国、37403
        • Erlanger Medical Center
    • Virginia
      • Norfolk、Virginia、美国、23507
        • Sentara Norfolk General
    • Washington
      • Seattle、Washington、美国、98195
        • University of Washington Medical Center
      • Leeds、英国、LS1 EX
        • The General Infirmary
      • Liverpool、英国、L14 3PE
        • Liverpool Heart and Chest Hospital
      • Manchester、英国、M13 9WL
        • Manchester Heart Center
      • Southampton、英国
        • Southampton University Hospital
      • Amsterdam、荷兰
        • Amsterdam University Medical Center
      • Nieuwegein、荷兰
        • St. Antonius Ziekenhuis
      • Rotterdam、荷兰、3015 CE
        • Erasmus MC University Medical Center
      • Barcelona、西班牙、08036
        • Hospital Clinic of Barcelona

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has an existing TV-ICD[iii] or S-ICD[iv]

  • Patient who is deemed to be at risk for MVT based on at least ONE of the following:

    • History of Non-Sustained MVT with LVEF ≤ 50%
    • History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant cardiac scar*
    • History of syncope deemed to be arrhythmic in origin
    • History of ischemic cardiomyopathy with LVEF ≤35%
    • History of non-ischemic cardiomyopathy with LVEF ≤35% and significant scar*
  • Patient who is willing and capable of providing informed consent (which is not to include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing associated with this investigation at an approved study site and at the intervals defined by this protocol

  • Patient who is age 18 years or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria:

  • Patient with an ongoing complication due to Cardiac Implantable Electronic Device (CIED) infection or CIED explant

  • Transvenous lead remnants within the heart from a previously implanted CIED (Note: transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)

  • Patient with a known LA thrombus

  • Patient with a ventricular arrhythmia due to a reversible cause

  • Patient indicated for implantation of a dual chamber pacemaker or cardiac resynchronization therapy (CRT)

  • Patient with another implanted medical device that could interfere with implant of the leadless pacemaker, such as an implanted inferior vena cava filter or mechanical tricuspid heart valve

  • Patient requires rate-responsive pacing therapy

  • Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)

  • Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable Angina) within 40 days

  • Inability to access femoral vein with a 21-French or larger inner diameter introducer sheath due to known anatomy condition, recent surgery, and/ or other relevant condition

  • Patient who has an active implanted electronic medical device intended for chronic use concomitantly with the study system, such as a left ventricular assist device (LVAD). Note that a temporary pacing wire is allowed.

  • Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)

  • Patient with a known cardiovascular anatomy that precludes implant in the right ventricle

  • Patient with a known allergy to any system components

  • Patient with a known or suspected intolerance to S-ICD conversion testing, based on physician discretion

  • Patient is not likely to have meaningful survival** for at least 12 months (documented or per investigator's discretion)

  • Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/ registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

  • Patient who is a woman of childbearing potential who is known to be pregnant at the time of study enrollment (method of assessment upon investigator's discretion)

    [i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.

[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.

[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated System implant

[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse Generator; Patients with an existing S-ICD PG subject to the electrical overstress field action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219, or future BSC S-ICD Pulse Generator

*Significant cardiac scar is defined as a scar involving at least one ventricular myocardial segment (i.e., basal infero-septum) as identified in the official findings of a cMRI, or nuclear viability study, or echo report by the interpreting radiologist/ cardiologist who is not affiliated with the study

**meaningful survival means that a patient has a reasonable quality of life and functional status

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MODULAR ATP Study Participants

All subjects that signed the informed consent were included.

Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware.

Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.

其他名称:
  • S-ICD 与无引线心脏起搏器 (LCP) 的通信

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety Endpoint 1: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 6 Months
大体时间:Implant through 6 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-Free Rate Subjects will be assessed for safety issues related to the procedure or system through 6 months post implant

Implant through 6 Months Post-Implant
Safety Endpoint 2: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 12 Months
大体时间:Implant through 12 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-free Rate

Subjects will be assessed for safety issues related to the procedure or system through 12 months post implant

Implant through 12 Months Post-Implant
Primary Effectiveness Endpoint 1: Percentage of Body Postures With Communication Success Between the S-ICD and EMPOWER PG
大体时间:At the 6 Month Follow-up

Communication Success between the S-ICD and EMPOWER PG

Data from subjects will be assessed for effectiveness of communication between S-ICD and the EMPOWER PG by evaluating if a paced beat is present during communication testing in four postures: upright, supine, and right and left side.

At the 6 Month Follow-up
Primary Effectiveness Endpoint 2: Percentage of Subjects Classified as a Pacing Capture Threshold (PCT) Responder
大体时间:At the 6 Month Follow-up

Proportion of Subjects with Adequate Pacing Capture Threshold

Effectiveness will be confirmed by evaluating the percentage of subjects considered to be a PCT Responder, defined as a subject with a PCT measurement of ≤ 2.0 V @ 0.4 ms pulse width

At the 6 Month Follow-up

次要结果测量

结果测量
措施说明
大体时间
Secondary Effectiveness Endpoint: Subject-specific Slope of EMPOWER PG Sensor-Indicated Rate to the Subject's Workload on Treadmill Test
大体时间:At the 3 Month Visit

Metabolic-Chronotropic Relation Slope (MCR Slope) from the Kay-Wilkoff Model

Using the Kay-Wilkoff model, data will be assessed to evaluate the proportionality of the EMPOWER PG's sensor-indicated rate to the subject's workload during the treadmill test

At the 3 Month Visit
Secondary Safety Endpoint
大体时间:Implant through 2 years post-implant

All-Cause Survival; data not reported as it is still being collected

Implant through 2 years post-implant

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Reinoud Knops, MD, PhD、Amsterdam University Medical Centre
  • 首席研究员:Lluis Mont, MD, PhD、Hospital Clinic, University of Barcelona
  • 首席研究员:Vivek Reddy, MD、The Mount Sinai Hospital
  • 首席研究员:Michael Lloyd, MD、Emory University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年7月20日

初级完成 (实际的)

2024年5月6日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2021年3月8日

首先提交符合 QC 标准的

2021年3月12日

首次发布 (实际的)

2021年3月15日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

There is no plan to share IPD with other researchers in this study.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅